The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples